Hemogenyx Pharmaceuticals annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Debt-to-Equity Ratio Growth & History (HEMO)
Hemogenyx Pharmaceuticals's debt-to-equity ratio was 1.68 for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.68 | −1.25 | −42.63% |
| 2024 | 2024-12-31 | 2.92 | 1.88 | +179.65% |
| 2023 | 2023-12-31 | 1.05 | 0.00 | +0.01% |
| 2022 | 2022-12-31 | 1.05 | 1.04 | +84223.01% |
| 2021 | 2021-12-31 | 0.00 | −1.83 | −99.93% |
| 2020 | 2020-12-31 | 1.83 | — | — |
Hemogenyx Pharmaceuticals quarterly debt-to-equity ratio
Q4.24
Q4.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 1.68 | −1.25 | −42.63% |
| Q4 2024 | 2024-12-31 | 2.92 | — | — |
Hemogenyx Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's debt-to-equity ratio decreased from 1.83 to 1.68, a change of −0.15. The latest reported quarter, Q4 2025, shows 1.68.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗